✦ LIBER ✦

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

✍ Scribed by Coplen, D.E.

Book ID: 122530790
Publisher: Elsevier Science
Year: 2009
Weight: 163 KB
Volume: 2009
Category: Article
ISSN: 0084-4071
DOI: 10.1016/S0084-4071(08)79096-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab plus interferon alfa-2a for

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

✍ Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracard 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 178 KB

Bevacizumab plus interferon alfa-2a for

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

✍ Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracard 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 178 KB

Re: Bevacizumab plus Interferon alfa-2a

Re: Bevacizumab plus Interferon alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial

✍ Shahrokh F. Shariat; Christian Bolenz; Pierre I. Karakiewicz 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Randomized Phase III Trial of Temsirolim

Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial

✍ Rini, B. I.; Bellmunt, J.; Clancy, J.; Wang, K.; Niethammer, A. G.; Hariharan, S 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 266 KB

Temsirolimus and bevacizumab, or sunitin

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

✍ Sylvie Négrier; Gwenaëlle Gravis; David Pérol; Christine Chevreau; Rémy Delva; J 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 236 KB

Axitinib with or without dose titration

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

✍ Rini, Brian I; Melichar, Bohuslav; Ueda, Takeshi; Grünwald, Viktor; Fishman, May 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 244 KB